Prostate Cancer P D:安体舒通与更低风险的前列腺癌相关

2020-03-23 AlexYang MedSci原创

安体舒通是一种便宜有效的利尿药,用于治疗高血压和心力衰竭。该药物通过与类固醇受体的非选择性结合也有抗雄激素效果,因此可能影响前列腺癌(PCa)风险。最近,有研究人员调查了安体舒通的使用与PCa风险的相

安体舒通是一种便宜有效的利尿药,用于治疗高血压和心力衰竭。该药物通过与类固醇受体的非选择性结合也有抗雄激素效果,因此可能影响前列腺癌(PCa)风险。最近,有研究人员调查了安体舒通的使用与PCa风险的相关性情况。为了便于比较,研究人员同时调查了不具有抗雄激素特性的噻嗪类利尿药剂与PCa风险的相关性情况。

研究是一个案例对照匹配的研究,使用了一个基于群体的数据。所有PCa案例的诊断时间为2014年到2016年,PCa案例与无PCa对照比例为1:5。研究发现,31591个案例中的3%的和156802个对照中的4%使用了安体舒通。多变量分析表明了PCa风险在那些使用了安体舒通的参与者中减少(OR 0.83;95%置信区间(CI):0.76-0.89),并且目前使用者(OR: 0.77, 95% CI: 0.69-0.86)与PCa风险减少的相关性要比过去使用者(OR: 0.88; 95% CI: 0.79-0.97)更强,并且随着使用剂量的增加,风险进一步减少(p-trend<0.001)。另外,研究人员没有观察到噻嗪类利尿药剂与PCa风险之间的相关性。研究人员也指出了处方差异和PSA测试频率差异产生的偏差可能对这些发现有影响。

最后,研究人员指出,PCa风险在那些使用安体舒通的男性中减少。研究人员也指出需要进一步调查安体舒通的化学预防效果。

原始出处:

Kerri Beckmann, Hans Garmo, Bertil Lindahl et al. Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer P D. 02 Mar 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791607, encodeId=b3121e91607b1, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 22 08:01:34 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364578, encodeId=ae7313645e84f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 25 03:01:34 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602251, encodeId=d9e8160225118, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Mar 25 03:01:34 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040689, encodeId=e1e01040689c2, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Mar 23 15:01:34 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791607, encodeId=b3121e91607b1, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 22 08:01:34 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364578, encodeId=ae7313645e84f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 25 03:01:34 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602251, encodeId=d9e8160225118, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Mar 25 03:01:34 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040689, encodeId=e1e01040689c2, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Mar 23 15:01:34 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
    2020-03-25 lsndxfj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791607, encodeId=b3121e91607b1, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 22 08:01:34 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364578, encodeId=ae7313645e84f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 25 03:01:34 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602251, encodeId=d9e8160225118, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Mar 25 03:01:34 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040689, encodeId=e1e01040689c2, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Mar 23 15:01:34 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
    2020-03-25 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791607, encodeId=b3121e91607b1, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 22 08:01:34 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364578, encodeId=ae7313645e84f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 25 03:01:34 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602251, encodeId=d9e8160225118, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Mar 25 03:01:34 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040689, encodeId=e1e01040689c2, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Mar 23 15:01:34 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
    2020-03-23 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

战“疫”关键期,肺癌患者如何做到“治疗不中断,染病低风险”?

新冠肺炎牵绊着全国人民的心,根据最新研究数据表明,重症患者主要为老年、合并有其他疾病以及免疫力低下的患者。肺癌患者相比正常人免疫力低下,而且还需要反复出入医院进行治疗和病情监测,增加感染的风险,一旦感

Int J Impot Res:阴道性交后损伤需要外科手术干预

最近,有研究人员报道了一个案例系列,即描述了自愿性交情况下女性阴道损伤的临床特征和治疗情况。其次,研究人员回顾了关于上述内容的文献情况。研究人员搜寻了所在单位的数据库,并排除了与自愿性行为无关的创伤,时间为2008年1月到2017年12月,包括了20名性交后阴道损伤而进行止血缝合的女性。她们的平均年龄为27.6±12.5 (范围 16-63),其中5名(25%)女性为生过孩子的,13名(65%)女

新冠肺炎血浆治疗方案增加内容:距首发症状时间不少于3周

国家卫健委微信公众号3月5日消息,为进一步做好新冠肺炎康复者恢复期血浆临床治疗工作,提高治愈率,国家卫生健康委、中央军委后勤保障部卫生局组织专家在总结、分析前期治疗工作的基础上,对治疗方案进行修订,形成了《新冠肺炎康复者恢复期血浆临床治疗方案(试行第二版)》。按照安全有效的原则,主要修订以下内容:一是捐献血浆者招募部分。根据康复者血浆产生具有中和作用抗体的时间,增加“距首发症状时间不少于3周”的内

盘点:听力障碍的治疗进展

【1】Cancers (Basel):鞘氨醇1-磷酸受体2能够诱导顺铂治疗的耳保护反应 耳毒性是基于铂化疗的一种主要的副作用,目前仍旧缺乏预防或者治疗该副作用的疗法。最近,有研究人员在不同的动物模型和细胞系中调查了鞘氨醇1-磷酸受体2(S1P2)在减弱顺铂诱导的耳毒性方面的作用。研究发现,S1P2敲除小鼠的耳毒性依赖于活性氧(ROS)的产生,一种特异性的激动剂CYM-5478能够激活

盘点:前列腺疾病治疗进展

【1】Sci Rep:先进的放疗技术和剂量增强对根治性前列腺切除术后挽救治疗毒性的影响 剂量递增放疗与强度调节放疗(IMRT)和成像指导的放疗(IGRT)的安全性和疗效在根治性前列腺切除术后挽救治疗(SRT)中仍旧不清楚。最近,有研究人员调查了这些先进的放疗技术和剂量增强对SRT毒性的影响。他们的多机构回顾性研究包括了421名患者,他们经历了SRT手术,平均剂量为66Gy。IMRT和

Eur Respir J:阻塞性睡眠呼吸暂停治疗与血压的关系

尽管该荟萃分析显示,CPAP/MAD预期的降血压效应为中等,但它确定了可以预测CPAP在血压控制方面可明显受益的患者特征。这些发现应谨慎解释,但是在确定OSA治疗患者与BP降低相关的潜在特征时,它们尤其重要。